Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study

Phase 1positiveEGL-003Positive

AI Analysis

Summary

Egle Therapeutics announced positive Phase 1 data for EGL-003, a Treg-selective IL-2 agonist, showing favorable safety and selective regulatory T cell expansion in healthy volunteers. The data were presented at the EADV congress and support advancement toward further development for autoimmune diseases.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Favorable safety and selective Treg expansion demonstrated across all four dose cohorts in healthy volunteer single ascending dose study

Importance:6/10

Sentiment:

0.80

Phase 1 dataautoimmune diseaseimmunologyIL-2 agonistregulatory T cellsatopic dermatitissafety datapharmacodynamics

Related Companies

$DTIL $HOST $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 30, 2026 5:01 AM

Read Original